JP2024009799A5 - - Google Patents

Info

Publication number
JP2024009799A5
JP2024009799A5 JP2023147032A JP2023147032A JP2024009799A5 JP 2024009799 A5 JP2024009799 A5 JP 2024009799A5 JP 2023147032 A JP2023147032 A JP 2023147032A JP 2023147032 A JP2023147032 A JP 2023147032A JP 2024009799 A5 JP2024009799 A5 JP 2024009799A5
Authority
JP
Japan
Prior art keywords
mpges
chr
inhibitor
nhc
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023147032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024009799A (ja
Filing date
Publication date
Priority claimed from PCT/EP2018/082146 external-priority patent/WO2019101826A1/en
Application filed filed Critical
Publication of JP2024009799A publication Critical patent/JP2024009799A/ja
Publication of JP2024009799A5 publication Critical patent/JP2024009799A5/ja
Pending legal-status Critical Current

Links

JP2023147032A 2017-11-22 2023-09-11 mPGES-1阻害剤としての化合物 Pending JP2024009799A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17203033.0 2017-11-22
EP17203033 2017-11-22
PCT/EP2018/082146 WO2019101826A1 (en) 2017-11-22 2018-11-22 Compounds as mpges-1 inhibitors
JP2020526121A JP7754623B2 (ja) 2017-11-22 2018-11-22 mPGES-1阻害剤としての化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020526121A Division JP7754623B2 (ja) 2017-11-22 2018-11-22 mPGES-1阻害剤としての化合物

Publications (2)

Publication Number Publication Date
JP2024009799A JP2024009799A (ja) 2024-01-23
JP2024009799A5 true JP2024009799A5 (enExample) 2025-12-18

Family

ID=60450482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526121A Active JP7754623B2 (ja) 2017-11-22 2018-11-22 mPGES-1阻害剤としての化合物
JP2023147032A Pending JP2024009799A (ja) 2017-11-22 2023-09-11 mPGES-1阻害剤としての化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020526121A Active JP7754623B2 (ja) 2017-11-22 2018-11-22 mPGES-1阻害剤としての化合物

Country Status (16)

Country Link
US (1) US11672787B2 (enExample)
EP (1) EP3713564B1 (enExample)
JP (2) JP7754623B2 (enExample)
KR (2) KR20250109241A (enExample)
CN (1) CN111417393A (enExample)
AU (1) AU2018371153B2 (enExample)
BR (1) BR112020010089A2 (enExample)
CA (1) CA3079483A1 (enExample)
ES (1) ES2963906T3 (enExample)
IL (1) IL274821A (enExample)
MX (1) MX2020005238A (enExample)
MY (1) MY207603A (enExample)
PL (1) PL3713564T3 (enExample)
SG (1) SG11202003743SA (enExample)
WO (1) WO2019101826A1 (enExample)
ZA (1) ZA202002103B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058033A1 (en) * 2017-04-05 2018-10-11 Khondrion Ip B.V. Treatment of mitochondrial diseases
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2025730B1 (en) * 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
WO2025242849A1 (en) * 2024-05-24 2025-11-27 Khondrion Ip B.V. Chromanyl derivatives for use in the treatment of bone disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02250831A (ja) * 1989-03-23 1990-10-08 Kuraray Co Ltd 3,4―ジヒドロ―2h―ベンゾピラン誘導体及びそれを有効成分とする抗消化性潰瘍剤
WO2006063466A1 (en) 2004-12-17 2006-06-22 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
DE102006053475A1 (de) 2006-11-14 2008-06-19 Eberhard-Karls-Universität Tübingen Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
DE102006058450A1 (de) 2006-12-12 2008-06-19 Eberhard-Karls-Universität Tübingen Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
SI3456707T1 (sl) * 2007-11-06 2020-10-30 Ptc Therapeutics, Inc. Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni
WO2009130242A1 (en) 2008-04-23 2009-10-29 Novasaid Ab Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases
DE102008027331A1 (de) 2008-06-07 2009-12-10 Friedrich-Alexander-Universität Erlangen-Nürnberg Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010127152A2 (en) 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
WO2012110860A1 (en) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2013038308A1 (en) 2011-09-15 2013-03-21 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
WO2013072825A1 (en) 2011-11-16 2013-05-23 Glenmark Pharmaceuticals S.A. Phtalazinone derivatives as mpegs -1 inhibitors
AR089939A1 (es) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
WO2013153535A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
US9388156B2 (en) * 2012-07-12 2016-07-12 Khondiron IP B.V. Chromanyl derivatives for treating mitochondrial disease
ES2622190T5 (es) 2012-07-12 2020-04-23 Khondrion Ip B V Derivados de cromanilo para tratar una enfermedad mitocondrial
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
ES2838625T3 (es) 2014-04-14 2021-07-02 Shanghai hengrui pharmaceutical co ltd Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
AU2016268975B2 (en) * 2015-05-22 2021-08-12 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage
WO2017060432A1 (en) * 2015-10-08 2017-04-13 Khondrion Ip B.V. Novel compounds for treating mitochondrial disease
CA3058033A1 (en) * 2017-04-05 2018-10-11 Khondrion Ip B.V. Treatment of mitochondrial diseases
AU2018371152B2 (en) * 2017-11-22 2024-02-08 Khondrion Ip B.V. Novel compounds for use in treating depression and migraine

Similar Documents

Publication Publication Date Title
JP2024009799A5 (enExample)
JP2020169171A5 (enExample)
JP2019529490A5 (enExample)
MX2024004789A (es) Esteroides neuroactivos y sus metodos de uso.
JP2005523922A5 (enExample)
JP2002543185A5 (enExample)
JPWO2020123827A5 (enExample)
JP2011527334A5 (enExample)
JP2010540508A5 (enExample)
JP2005515978A5 (enExample)
JP2012505871A5 (enExample)
JP2020507589A5 (enExample)
JP2010501478A5 (enExample)
JP2004500426A5 (enExample)
JPWO2023099612A5 (enExample)
JP2008546770A5 (enExample)
JP2012515195A5 (enExample)
RU2374228C2 (ru) Производные 4-фенилпиперидина в качестве ингибиторов ренина
JPWO2020006432A5 (enExample)
JP2002530378A5 (enExample)
JP2005516898A5 (enExample)
JP2008521934A5 (enExample)
RU2007125130A (ru) Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1
JP2004536079A5 (enExample)
JP2020509043A5 (enExample)